Mysterious package received at North Canaan facility tests negative for Plague, Anthrax
Over 300 people 'decontaminated' due to suspicious package incident in North Canaan
Over 300 people had to be decontaminated after a mysterious package arrived at the facility.
The Connecticut Department of Public Health confirmed that the mysterious package received negative test results for Anthrax, Burkholderia Species, Plague, Tularemia and Smallpox. Additionally, a negative Ricin test was confirmed.
Officials continue to ensure that there is no risk to the public and no symptoms or illnesses reported by employees who had to be decontaminated.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 17 cents in second-quarter 2025 compared with the year-ago period's EPS of 6 cents. However, the metric missed the Zacks Consensus Estimate by a penny. HIMS' Revenues in Detail Hims & Hers registered revenues of $544.8 million in the second quarter, up 72.6% year over year. The figure missed the Zacks Consensus Estimate by 1.5%. Solid revenues from the Online channel drove the top line despite being partially offset by Wholesale revenues. Shares of this company lost nearly 12.9% in today's pre-market trading. Hims & Hers' Segment Details Hims & Hers' operations consist of two channels — Online Revenues and Wholesale Revenues. In the quarter under review, Online Revenues of $536.9 million reflected a surge of 74.9% year over year on a reported basis. During the reported quarter, subscribers were 2.4 million (up 30.8% year over year). This was primarily driven by increased traffic to Hims & Hers' platform (through websites and mobile applications), resulting from its marketing activities and improved onsite and customer onboarding experiences and consumer adoption of the company's personalized offerings across its business, including GLP-1 weight loss offerings. Monthly online revenue per average subscriber increased 29.8% year over year to $74 in the second quarter, primarily resulting from subscriber uptake of personalized offerings across Hims & Hers' business, including its GLP-1 weight loss offering, along with changes in product mix. Wholesale Revenues totaled $7.9 million, down 9.7% year over year. Hims & Hers Health, Inc. Price, Consensus and EPS Surprise Hims & Hers Health, Inc. price-consensus-eps-surprise-chart | Hims & Hers Health, Inc. Quote HIMS' Margin Analysis In the second quarter, Hims & Hers' gross profit increased 62.2% year over year to $416.2 million. However, the gross margin contracted 491 basis points (bps) to 76.4%. Marketing expenses jumped 50.3% year over year to $217.9 million, while technology and development expenses increased 102.9% year over year to $37.8 million. General and administrative expenses rose 65.9% year over year to $67.3 million, while operations and support expenses increased 60.4% year over year to $66.5 million. Operating expenses of $389.5 million increased 58.6% year over year. Operating profit totaled $26.7 million, reflecting a 142.3% surge from the year-ago quarter. The operating margin in the second quarter expanded 141 bps to 4.9%. Hims & Hers' Financial Position Hims & Hers exited second-quarter 2025 with cash and cash equivalents and short-term investments of $1.14 billion compared with $322.7 million at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $89.9 million compared with $79.4 million a year ago. HIMS' Outlook Hims & Hers has provided its revenue outlook for the third quarter and reiterated the same for 2025. The company projects revenues for the third quarter of 2025 in the range of $570 million to $590 million, reflecting an uptick of 42-47% year over year. The Zacks Consensus Estimate is pegged at $583.3 million. For the full year, the company continues to project revenues in the range of $2.3 billion to $2.4 billion (representing growth of 56-63% from 2024 levels). The Zacks Consensus Estimate is pegged at $2.35 billion. Our Take on Hims & Hers Hims & Hers' robust improvement in the top and bottom lines and strength in its Online revenue channel in second-quarter 2025 were promising. The increase in subscribers and monthly online revenue per average subscriber during the quarter was encouraging. The expansion of the operating margin during the quarter bodes well. In July, HIMS closed its acquisition of ZAVA, expanding its presence in the U.K. and establishing a foundation in other strategic markets such as Germany, Ireland and France. Per management, the acquisition will likely accelerate the company's ability to expand into markets beyond Europe. In 2026, Hims & Hers expects to enter Canada with an initial focus on a holistic weight loss program, timed to align with the anticipated first-ever availability of generic semaglutide globally. These raise our optimism about the stock. However, Hims & Hers' lower-than-expected results in the second quarter of 2025 and lower Wholesale revenues were disappointing. The gross margin contracted due to rising product costs, which do not bode well for the stock. HIMS' Zacks Rank and Other Key Picks Hims & Hers currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
SCH Capital Holdings, Inc. Adds Health Care Compensation Management Technology Capability to Portfolio
CHICAGO--(BUSINESS WIRE)--SCH Capital Holdings, Inc., the nation's leading human capital information management holding company for health care and not-for-profit/tax-exempt organizations, has acquired Boston-based Statera. "When we combine Statera's focus on academic medical centers alongside Clinician Nexus's integrated delivery systems expertise, we are able to serve the entire health care marketplace with specialized compensation management expertise in both segments." Formed in 2020, Statera is a group of human-focused compensation experts and health care technologists who provide timely and actionable compensation and care insights to hospitals, medical groups, and clinicians. Statera's platform offers a comprehensive suite of tools that optimize clinical team performance and automate compensation administration. Statera will continue to enable health systems to automate physician compensation through its technology platform as part of Clinician Nexus, a SCH Capital Holdings, Inc. technology company. Together, these combined capabilities will provide health care organizations with a broad mix of technology tools that empower health systems and medical groups to align compensation, productivity, and incentives for their physicians and APPs. 'When we combine Statera's focus on academic medical centers alongside Clinician Nexus's integrated delivery systems expertise, we are able to serve the entire health care marketplace with specialized compensation management expertise in both segments,' said Ted Chien, President and CEO of SCH Capital Holdings, Inc. 'We are excited to join the SCH Capital Holdings, Inc., family and integrate our expertise into the Clinician Nexus brand,' said Amy Jackson, CEO of Statera. 'The company's gold standard reputation and Clinician Nexus's established platform will enable us to reach new markets. Together, we'll be able to deliver the next generation of compensation management technology to a broader audience and make a greater impact across the health care ecosystem.' About SCH Capital Holdings, Inc. SCH Capital Holdings, Inc., is the parent company of independent operating brands SullivanCotter, Clinician Nexus, Lotis Blue Consulting and C3 Nonprofit Consulting Group. This collection of complementary brands helps organizations solve complex workforce issues by enabling people, processes and technology aimed at large-scale business transformation. For more information, email info@ or call 888.739.7039.
Business Wire
6 hours ago
- Business Wire
Butterfly Network Advances AI-Powered Aortic Valve and Aorta Screening with New Research and Training Tools
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced its role in new research demonstrating the potential for machine learning (ML) models to support early detection of aortic stenosis (AS) using handheld ultrasound devices. The study, conducted by Tufts Medical Center and published in European Heart Journal – Imaging Methods and Practice, demonstrates that a ML model fine-tuned for use on Butterfly iQ+ devices can achieve high accuracy in identifying AS. The findings support the value of ML model development, and ultimately, are a positive step toward portable screening for earlier detection of this life-threatening condition. Aortic stenosis, a narrowing of the aortic valve, affects over 13% of Americans over 75 years old and is often missed until it's advanced and symptomatic. Studies(1, 2) suggest that a significant number of AS cases remain undiagnosed, particularly among underserved and aging populations. This delay in diagnosis is associated with higher risk procedures, worse outcomes, and increased healthcare costs. As earlier identification and treatments of AS are increasingly associated with better patient outcomes, the need for upstream, accessible screening is critical. 'This research shows a promising path forward where lower-level providers, not just cardiologists or trained sonographers, could screen for aortic stenosis using AI-assisted handheld ultrasound,' said Dr. John Martin, co-author of the study and Butterfly's Chief Medical Officer Emeritus. 'This opens the door to early detection in a wide variety of care venues including primary care offices, long term care facilities, urgent care facilities and even in the home.' The study validated that an ML model trained on hospital-grade ultrasound images performed well when adapted to Butterfly's handheld ultrasound device. After fine-tuning the final layer of a neural network, researchers achieved an area under the receiver operator characteristic curve (AUROC) of 0.94 for differentiating between no aortic stenosis and any degree of aortic stenosis on handheld ultrasound images – a level of accuracy that supports potential clinical use in screening workflows. In a related development, Butterfly has just released the latest expansion of its Butterfly ScanLab™ AI-powered ultrasound education app: an Aorta Exam Protocol. This educational app harnesses animations, anatomical labeling, and a quality indicator to help teach users how to scan the abdominal aorta and recognize normal anatomy. With that training, users can then use POCUS to detect life-threatening conditions like abdominal aortic aneurysms (AAA) and dissections. Designed for ease of use on an iPad, the module is included in every Butterfly membership and compatible with existing Butterfly probes. Joseph DeVivo, President, CEO, and Chairman of Butterfly Network concluded, 'Early detection saves lives, but access to imaging remains a major barrier. This work is about democratizing diagnostics. With AI and education working hand in hand, we're empowering more providers to deliver proactive care in places that were never possible before.' About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit:
